# A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.

> **NCT02821182** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 20 (actual)

## Conditions studied

- Melanoma

## Interventions

- **RADIATION:** stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT02821182
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2018-09-09
- **Final completion:** 2019-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821182, "A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02821182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*